These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37890967)

  • 1. Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol.
    Vivash L; Johns H; Churilov L; MacPhail S; Casillas-Espinosa P; Malpas C; Shultz SR; Tailby C; Wijayath M; Reutens D; Gillinder L; Perucca P; Carney P; Nicolo JP; Lawn N; Kwan P; Velakoulis D; Hovens CM; O'Brien TJ
    BMJ Open; 2023 Oct; 13(10):e075888. PubMed ID: 37890967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy.
    Casillas-Espinosa PM; Anderson A; Harutyunyan A; Li C; Lee J; Braine EL; Brady RD; Sun M; Huang C; Barlow CK; Shah AD; Schittenhelm RB; Mychasiuk R; Jones NC; Shultz SR; O'Brien TJ
    Elife; 2023 Mar; 12():. PubMed ID: 36892461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial.
    Vivash L; Bertram KL; Malpas CB; Marotta C; Harding IH; Kolbe S; Fielding J; Clough M; Lewis SJG; Tisch S; Evans AH; O'Sullivan JD; Kimber T; Darby D; Churilov L; Law M; Hovens CM; Velakoulis D; O'Brien TJ
    BMJ Open; 2021 Dec; 11(12):e055019. PubMed ID: 34916328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia.
    Vivash L; Malpas CB; Churilov L; Walterfang M; Brodtmann A; Piguet O; Ahmed RM; Bush AI; Hovens CM; Kalincik T; Darby D; Velakoulis D; O'Brien TJ
    BMJ Open; 2020 Nov; 10(11):e040100. PubMed ID: 33199422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Felbamate add-on therapy for drug-resistant focal epilepsy.
    Shi LL; Bresnahan R; Martin-McGill KJ; Dong J; Ni H; Geng J
    Cochrane Database Syst Rev; 2022 Aug; 8(8):CD008295. PubMed ID: 35914010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
    McEvoy NL; Clarke JL; Mc Elvaney OJ; Mc Elvaney OF; Boland F; Hyland D; Geoghegan P; Donnelly K; Friel O; Cullen A; Collins AM; Fraughen D; Martin-Loeches I; Hennessy M; Laffey JG; Mc Elvaney NG; Curley GF
    Trials; 2021 Apr; 22(1):288. PubMed ID: 33874981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classic ketogenic diet versus further antiseizure medicine in infants with drug-resistant epilepsy (KIWE): a UK, multicentre, open-label, randomised clinical trial.
    Schoeler NE; Marston L; Lyons L; Halsall S; Jain R; Titre-Johnson S; Balogun M; Heales SJR; Eaton S; Orford M; Neal E; Reilly C; Eltze C; Stephen E; Mallick AA; O'Callaghan F; Agrawal S; Parker A; Kirkpatrick M; Brunklaus A; McLellan A; McCullagh H; Samanta R; Kneen R; Tan HJ; Devlin A; Prasad M; Rattihalli R; Basu H; Desurkar A; Williams R; Fallon P; Nazareth I; Freemantle N; Cross JH;
    Lancet Neurol; 2023 Dec; 22(12):1113-1124. PubMed ID: 37977712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyunsaturated fatty acid supplementation for drug-resistant epilepsy.
    Sarmento Vasconcelos V; Macedo CR; de Souza Pedrosa A; Pereira Gomes Morais E; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011014. PubMed ID: 27536971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brivaracetam add-on therapy for drug-resistant epilepsy.
    Bresnahan R; Panebianco M; Marson AG
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD011501. PubMed ID: 30920649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatments for seizures in catamenial (menstrual-related) epilepsy.
    Maguire MJ; Nevitt SJ
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013225. PubMed ID: 34528245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke.
    Nicolo JP; Chen Z; Moffat B; Wright DK; Sinclair B; Glarin R; Neal A; Thijs V; Seneviratne U; Yan B; Cloud G; O'Brien TJ; Kwan P
    BMJ Open; 2021 May; 11(5):e043488. PubMed ID: 33972334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivaracetam add-on therapy for drug-resistant epilepsy.
    Bresnahan R; Panebianco M; Marson AG
    Cochrane Database Syst Rev; 2022 Mar; 3(3):CD011501. PubMed ID: 35285519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxcarbazepine add-on for drug-resistant focal epilepsy.
    Bresnahan R; Atim-Oluk M; Marson AG
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012433. PubMed ID: 32129501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Content or context? A study protocol for a three-arm parallel randomised controlled trial of R
    Higson L; O'Brien TJ; Rayner G; Alpitsis R; Winton-Brown T
    BMJ Open; 2023 Oct; 13(10):e072835. PubMed ID: 37793938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.